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Introduction {#s1}
============

Chemokines are small glycoproteins that contribute to the regulation of various biological processes [@pone.0108953-Locati1]. CXCL12, also known as stromal cell-derived factor 1(SDF-1), is a small chemotactic cytokine belonging to the CXC chemokine family that is constitutively expressed in various organs [@pone.0108953-Muller1]. It contributes to the regulation of leukocyte trafficking and many essential biological processes, including cardiac and neuronal development, stem cell motility, neovascularization, and tumorigenesis [@pone.0108953-Ma1]--[@pone.0108953-Petit1].

CXCL12 binds primarily to the CXCR4 receptor, resulting in a CXCL12/CXCR4 receptor-ligand system involving a one-on-one interaction [@pone.0108953-Bleul1], [@pone.0108953-Tachibana1]. CXCR4 may play a vital role in the metastatic processes of many types of cancers, including colorectal, breast and oral squamous cell carcinoma [@pone.0108953-Schimanski1]--[@pone.0108953-Uchida1]. Further research has emphasized the key role of CXCR4 in tumor cell malignancy; the activation of CXCR4 by CXCL12 has been shown to induce the migration, invasion and angiogenesis of tumor cells [@pone.0108953-Chen1], [@pone.0108953-Mori1].

CXCL12 is located on chromosome 10q11.1 and has a G→A mutation at position 801 in the 3′-untranslated region in its β transcriptional splice variant [@pone.0108953-Shirozu1], [@pone.0108953-Watanabe1]. The CXCL12 G801A polymorphism may be essential to increasing the production of a CXCL12 protein that has been shown to be associated with an increased risk of various kinds of cancers, such as breast cancer, lung cancer and lymphoma [@pone.0108953-Zafiropoulos1]--[@pone.0108953-deOliveira1]. Recently, numerous studies have shown that the CXCL12 G801A polymorphism occurs in different types of cancers, but the results have been too inconsistent to be conclusive. In addition, the sample size of each study is relatively small; thus, their statistical power is too low to detect associations between the CXCL12 G801A polymorphism and cancer risk. Meta-analysis is a powerful method for resolving inconsistent findings from a relatively large number of subjects. To solve the problem of inadequate statistical power and conflicting results, we performed this meta-analysis of published case-control studies.

Materials and Methods {#s2}
=====================

Literature Search {#s2a}
-----------------

Two investigators independently searched for eligible studies of the associations between CXCL12 G801A polymorphism and cancer risk. Studies published through March 2014 were identified through a computerized search of PubMed without language limitation. The key words used in this search were as follows: (CXCL12, SDF-1 or rs1801157) and (cancer, tumor, carcinoma or neoplasm) and polymorphism. The references of all identified publications were also searched for additional studies. Studies included in this meta-analysis had to meet the following inclusion criteria: (a) used a case-control study design, (b) evaluated CXCL12 G801A polymorphism and cancer risk, (c) reported detailed genotype frequencies of cases and controls or these could be calculated from the text of the manuscript, and (d) the control subjects were in agreement with the Hardy-Weinberg equilibrium (HWE).

Data Extraction {#s2b}
---------------

Two investigators extracted the data independently, and disagreements were settled by discussion. The following data were extracted from the eligible studies: the first author\'s name, year of publication, country of origin, ethnicity, the source of controls, and numbers of genotyped cases and controls. If the data was not available, study authors were contacted to request missing data.

Statistical Analysis {#s2c}
--------------------

ORs and their 95% CIs were used to determine the strength of association between the CXCL12 G801A polymorphism and cancer risk. The significance of the pooled OR was determined using the Z test, and *P*\<0.05 was considered statistically significant. Additive (A vs. G), dominant (GA+AA vs. GG), and recessive (AA vs. GG+GA) genetic models were investigated. Subgroup analysis was performed by ethnicity, cancer type (if one cancer type contained less than two studies, it was defined as "other"), and source of controls, either hospital or population controls. HWE was tested using the chi-square test among controls, and *P*\<0.05 was considered a significant departure from HWE. If the *P* value for heterogeneity was \>0.05 and *I* ^2^\<50%, indicating an absence of heterogeneity between studies, the fixed-effects model (the Mantel-Haenszel method) was used. In contrast, if either the *P* value for heterogeneity was ≤0.05 or *I* ^2^ was ≥50%, indicating heterogeneity among the studies, the more appropriate random-effects model (the DerSimonian and Laird method) was used. Sensitivity analyses were performed to assess the stability of the results. Funnel plots and Egger\'s linear regression test were used to diagnose potential publication bias, and *P*\<0.05 was used to indicate possible publication bias. All analyses were performed using Stata software. *P* values were based on two-sided tests.

Results {#s3}
=======

Characteristics of Eligible Studies {#s3a}
-----------------------------------

Our meta-analysis was performed according to guidelines of the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA) statement ([Checklist S1](#pone.0108953.s001){ref-type="supplementary-material"}) and "Meta-analysis on Genetic Association Studies" statement ([Checklist S2](#pone.0108953.s002){ref-type="supplementary-material"}). [Figure 1](#pone-0108953-g001){ref-type="fig"} graphically illustrates the study flow chart. The literature search yielded 79 potentially relevant articles. After screening the titles and abstracts, 46 articles were excluded because of obvious irrelevance. In addition, after reading the full text of the 33 remaining articles, 8 articles were excluded for the following reasons: article was a review (n = 1), articles lacked controls (n = 2), articles had insufficient data (n = 2), and articles deviated from HWE (n = 3). Articles that reported data for different types of cancers were treated as independent studies. Thus, 25 articles [@pone.0108953-Zafiropoulos1]--[@pone.0108953-Cai1] (30 independent case-control studies) met the inclusion criteria; they included 4,435 cancer cases and 6,898 controls. Data collected from the included studies are summarized in [Table 1](#pone-0108953-t001){ref-type="table"}.

![Flow chart of study selection in the meta-analysis.](pone.0108953.g001){#pone-0108953-g001}

10.1371/journal.pone.0108953.t001

###### Characteristics of eligible studies included in the meta-analysis.

![](pone.0108953.t001){#pone-0108953-t001-1}

  *author*                                           *year*         *cancer*         *country*   *ethnicity*   *control source*   *HWE*   *Cases*   *controls*                   
  ------------------------------------------------- -------- ---------------------- ----------- ------------- ------------------ ------- --------- ------------ ---- ----- ----- ----
  Zafiropoulos [@pone.0108953-Zafiropoulos1]          2004       breast cancer        Greece      Caucasian           HB          0.764     98         136       30   101   92    19
                                                      2004       bladder cancer       Greece      Caucasian           HB          0.124     31          32       5    67    71    10
                                                      2004        skin cancer         Greece      Caucasian           HB          0.262     64          38       8    169   164   30
  Razmkhah [@pone.0108953-Razmkhah1]                  2005        lung cancer          Iran         Asian             HB          0.504     25          38       9    145   97    20
  Razmkhah [@pone.0108953-Razmkhah2]                  2005       breast cancer         Iran         Asian             HB          0.682     105        139       34   101   67    13
  Hidalgo-Pascual [@pone.0108953-HidalgoPascual1]     2007     colorectal cancer       Spain      Caucasian           PB          0.77      212        128       9    319   172   25
  Hirata [@pone.0108953-Hirata1]                      2007      prostate cancer        Japan        Asian             HB          0.651     72          78       17   91    63    13
  Dimberg [@pone.0108953-Dimberg1]                    2007     colorectal cancer      Sweden      Caucasian           HB          0.117     84          62       5    81    56    4
  de Oliveira [@pone.0108953-deOliveira2]             2007            CML             Brazil      Caucasian           HB          0.628     10          11       4    39    18    3
  Khademi [@pone.0108953-Khademi1]                    2008    head and neck cancer     Iran         Asian             HB          0.504     64          84       8    145   97    20
  Vairaktaris [@pone.0108953-Vairaktaris1]            2008        oral cancer          Mixed      Caucasian           PB          0.448     104         51       4    55    41    5
  Lin [@pone.0108953-Lin1]                            2009       breast cancer         China        Asian             HB          0.621     106         98       16   175   136   23
  Vazquez-Lavista [@pone.0108953-VzquezLavista1]      2009       bladder cancer       Mexico        Mixed             PB          0.822     29          15       3    83    39    4
  de Oliveira [@pone.0108953-deOliveira1]             2009       breast cancer        Brazil      Caucasian           HB          0.939     59          41       3    61    32    4
                                                      2009            NHL             Brazil      Caucasian           HB          0.356     36          33       1    59    26    5
                                                      2009             HL             Brazil      Caucasian           HB          0.356     22          10       4    59    26    5
  Kruszyna [@pone.0108953-Kruszyna1]                  2010       breast cancer        Poland      Caucasian           PB          0.686     123         61       9    136   58    5
  Kruszyna [@pone.0108953-Kruszyna2]                  2010      laryngeal cancer      Poland      Caucasian           PB          0.114     69          46       3    181   67    2
  Lee [@pone.0108953-Lee1]                            2011           NSCLC             China        Asian             HB          0.379     99         112       36   171   136   21
  de Oliveira [@pone.0108953-deOliveira3]             2011       breast cancer        Brazil      Caucasian           HB          0.758     32          21       2    37    15    2
  Cacina [@pone.0108953-Cacina1]                      2012     endometrial cancer     Turkey        Asian             HB          0.061     49          52       12   69    64    6
  Tee [@pone.0108953-Tee1]                            2012      cervical cancer       Taiwan        Asian             HB          0.697     37          29       10   164   140   33
  Kucukgergin [@pone.0108953-Kucukgergin1]            2012       bladder cancer       Turkey        Asian             HB          0.35      58          58       26   94    80    23
  Liarmakopoulos [@pone.0108953-Liarmakopoulos1]      2013       gastric cancer       Greece      Caucasian           HB          0.116     39          43       6    205   229   46
  Perim [@pone.0108953-deLourdesPerim1]               2013            ALL             Brazil      Caucasian           PB          0.72      33          18       3    46    11    1
  Razmkhah [@pone.0108953-Razmkhah3]                  2013       gastric cancer        Iran         Asian             HB          0.504     66          48       10   145   97    20
                                                      2013     colorectal cancer       Iran         Asian             HB          0.504     62          39       8    145   97    20
  Shi [@pone.0108953-Shi1]                            2013     colorectal cancer      Taiwan        Asian             PB           0.1      141        113       4    248   52    0
  Kontogianni [@pone.0108953-Kontogianni1]            2013       breast cancer        Greece      Caucasian           HB          0.585     114        118       29   247   198   35
  Cai [@pone.0108953-Cai1]                            2013     renal cell cancer       China        Asian             HB          0.127     150        111       61   237   136   29

CML: chronic myeloid leukemia; NHL: non-hodgkin lymphoma; HL: hodgkin lymphoma; NSCLC: non small cell lung cancer; ALL:acute lymphocytic leukemia; HB: hospital-based; PB:population-based.

Results of the Meta-analysis {#s3b}
----------------------------

A significant association between CXCL12 G801A polymorphism and cancer risk was found under an additive genetic model (OR = 1.30, 95% CI = 1.16--1.45), a dominant genetic model (OR = 1.37, 95%CI = 1.19--1.58), and a recessive genetic model (OR = 1.38, 95% CI = 1.13--1.69). Subgroup analysis stratified by ethnicity also suggested a significant association between CXCL12 G801A polymorphism and cancer risk in the Asian subgroup under an additive genetic model (OR = 1.45, 95% CI = 1.23--1.70), a dominant genetic model (OR = 1.56, 95%CI = 1.27--1.92) ([Figure 2](#pone-0108953-g002){ref-type="fig"}), and a recessive genetic model (OR = 1.71, 95% CI = 1.41--2.07). In the Caucasian subgroup, a significant association was found under an additive genetic model (OR = 1.16, 95%CI = 1.00--1.34) and a dominant genetic model (OR = 1.21, 95%CI = 1.01--1.44).

![Forest plot of CXCL12 G801A polymorphism and cancer risk under a dominant genetic model (GA+AA vs. GG) stratified by ethnicity.](pone.0108953.g002){#pone-0108953-g002}

Furthermore, in the analysis by stratified cancer type, a significantly increased risk was found in breast cancer and lung cancer under all genetic models. In addition, under the additive and dominant genetic models, a significantly increased risk was found in "other" cancers. However, no significant association with this polymorphism was observed in bladder, colorectal and gastric cancers. Base on subgroup analysis by source of controls (hospital or population controls), a significant association was observed in hospital-based studies under all genetic models ([Table 2](#pone-0108953-t002){ref-type="table"}).

10.1371/journal.pone.0108953.t002

###### Pooled ORs and 95% CIs of the association between CXCL12 G801A polymorphism and cancer risk.

![](pone.0108953.t002){#pone-0108953-t002-2}

                            *A vs G*       *GA/AA vs GG*   *AA vs GA/GG*                                                              
  -------------------- ------------------ --------------- --------------- ------------------ ------ ------- ------------------ ------ -------
  overall               1.30(1.16--1.45)       67.3            0.000       1.37(1.19--1.58)   66.0   0.000   1.38(1.13--1.69)   33.3   0.041
  ethnicity                                                                                                                           
  Asian                 1.45(1.23--1.70)       70.8            0.000       1.56(1.27--1.92)   71.0   0.000   1.71(1.41--2.07)   40.8   0.062
  Caucasian             1.16(1.00--1.34)       52.9            0.007       1.21(1.01--1.44)   51.9   0.008   1.11(0.87--1.41)   12.0   0.316
  Cancer type                                                                                                                         
  Breast cancer         1.32(1.17--1.48)        0.0            0.537       1.43(1.23--1.66)   0.0    0.436   1.41(1.06--1.87)   0.0    0.843
  Bladder cancer        1.22(0.97--1.55)        0.0            0.577       1.19(0.87--1.62)   0.0    0.731   1.58(0.96--2.61)   0.0    0.744
  Lung cancer           1.65(1.34--2.04)        0.0            0.610       1.80(1.36--2.39)   17.6   0.271   2.24(1.41--3.57)   0.0    0.475
  colorectal cancer     1.33(0.76--2.34)       91.6            0.000       1.43(0.73--2.80)   91.7   0.000   0.86(0.53--1.41)   36.6   0.192
  Gastric cancer        0.98(0.77--1.25)        0.0            0.505       1.02(0.74--1.39)   0.0    0.637   0.87(0.48--1.55)   0.0    0.476
  Others                1.31(1.06--1.61)       68.8            0.000       1.36(1.05--1.75)   66.7   0.001   1.47(0.96--2.26)   51.3   0.020
  Source of controls                                                                                                                  
  HB                    1.27(1.15--1.41)       49.1            0.004       1.34(1.18--1.52)   45.0   0.011   1.49(1.28--1.75)   28.1   0.105
  PB                    1.42(0.94--2.14)       86.8            0.000       1.49(0.93--2.40)   86.6   0.000   1.09(0.69--1.73)   46.1   0.085

Sensitivity Analysis {#s3c}
--------------------

A single study was excluded each time to evaluate the effect of an individual study on the combined ORs and 95% CIs. The omission of any single study did not significantly change the pooled effects of the additive, dominant and recessive genetic models; these findings confirmed that the meta-analysis results were statistically robust and that our results were reliable and stable (data not shown).

Publication Bias {#s3d}
----------------

Begg\'s funnel plot and Egger\'s test were performed to assess the publication bias of this set of publications. The shape of the funnel plot did not show obvious publication bias ([Figure 3](#pone-0108953-g003){ref-type="fig"}). Similarly, Egger\'s test revealed no evidence of publication bias (P = 0.996 for the additive genetic model; P = 0.953 for the dominant genetic model; and P = 0.342 for the recessive genetic model).

![Funnel plot for studies of the association of CXCL12 G801A polymorphism and cancer risk under a dominant genetic model (GA+AA vs. GG).](pone.0108953.g003){#pone-0108953-g003}

Discussion {#s4}
==========

CXCL12 is primarily produced by stromal cells and is important for the growth, angiogenesis and metastasis of tumor cells [@pone.0108953-Nagasawa1], [@pone.0108953-Bleul2]. The CXCL12 G801A polymorphism may be essential to increasing the production of CXCL12 protein. Furthermore, overexpression of CXCL12 is associated with the development and metastasis of many kinds of cancers. The CXCL12 G801A polymorphism has been investigated in various types of cancers. However, the results of previous studies conflicted about the association between CXCL12 G801A polymorphism and cancer risk. In order to resolve this controversy, the present meta-analysis, which included 4,435 cases and 6,898 controls from 30 case-control studies, explored the association between CXCL12 G801A polymorphism and cancer risk. Our results indicated that CXCL12 G801A polymorphism was associated with an increased risk of cancers.

Additionally, our study contributes the results of subgroup analyses stratified by ethnicity, cancer type and source of controls. Our results indicated that the CXCL12 G801A polymorphism was associated with an increased risk of cancers, especially for breast and lung cancer. However, no significant association was observed for bladder, colorectal and gastric cancers. This is maybe because cancers types differ by carcinogenic mechanisms and environmental exposures and have disparate responses to CXCL12 G801A genotypes. In addition, gene-gene and gene-environment interactions may influence the association between CXCL12 G801A polymorphism and susceptibility to specific cancers [@pone.0108953-Singh1]--[@pone.0108953-Beheshti1]. Furthermore, for some cancer types defined as "other", only a few studies were published; therefore, it was difficult to detect small, but meaningful associations. Consequently, large-scale and detailed studies are needed to examine these relationships.

In the subgroup analysis by ethnicity, the CXCL12 G801A polymorphism was found to confer an increased cancer risk among Asians under all the genetic models, whereas in the Caucasian subgroup, a significant association was only observed under an additive genetic model and a dominant genetic model. The mechanism that explains this ethnic difference is unknown, but differences in genetic backgrounds and life-styles may contribute to different genetic characteristics and susceptibility to specific cancers. In the present meta-analysis, we failed to find significant relationships between CXCL12 G801A polymorphism and cancer risk in ethnic groups besides Asian and Caucasian. Therefore, more studies in other ethnic groups may be necessary for further progress in this area.

In the subgroup analysis stratified by the source of controls, significant associations were observed in hospital-based studies but not in population-based studies. However, most of the included studies were hospital-based because hospital controls are more readily available. Therefore, the findings in this subgroup should be interpreted with caution. Additional population-based studies are needed to better evaluate this association.

We identified previous genome-wide studies relevant to our research, such as those conducted in breast cancer and lung cancer [@pone.0108953-Lan1]--[@pone.0108953-Zhang1]. However, these studies were not included in our analysis because their raw data was not available. No significant association between CXCL12 G801A polymorphism and cancer risk was observed in those studies, which conflicts with our results. Possible reasons for this inconsistency are that genome-wide association studies are limited by their relatively small samples and can\'t contain all kinds of populations.

Two meta-analyses similar to that presented herein were performed by Gong et al. [@pone.0108953-Gong1] in 2012 and MA et al. [@pone.0108953-Ma2] in 2012, who also investigated the influence of CXCL12 G801A polymorphism on susceptibility to cancers, with similar conclusions. There were two main differences between these two studies and our study. First, the study of Gong et al. included two articles that deviated from HWE, which were excluded from our study. Second, the literature searches of the two prior meta-analyses were conducted before October 2011 and May 2011, respectively. Since then, several additional studies of the CXCL12 G801A polymorphism and cancer risk were published. Therefore, the sample was larger and the statistical power was greater in our meta-analysis.

We conducted the largest and most comprehensive quantitative meta-analysis of the relationship between CXCL12 G801A polymorphisms and cancer risk. Nevertheless, we recognize some limitations of this meta-analysis. First, our meta-analysis was based primarily on unadjusted ORs with 95% CIs because potential correlative factors, such as environmental factors and other lifestyle habits, were not available. Second, the meta-analysis was limited by the relatively small number of available studies, which limited our ability to perform subgroup analysis for every type of cancer. Third, our analysis was limited to Asian and Caucasian ethnicities, and it is uncertain whether these results are generalizeable to other populations. In addition, cancer is a multi-factorial disease that results from complex interactions between many genetic and environmental factors. Therefore, a single gene or single environmental factor is unlikely to explain cancer susceptibility.

In conclusion, this meta-analysis suggested that CXCL12 G801A polymorphism was associated with an increased risk of cancer based on current published data. In the future, large-scale well-designed studies with more information about potential correlative factors are needed to better estimate possible gene-gene or gene-environment interactions.
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